# Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease

Study · id `cardio:ct-nct04059913` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04059913](<https://clinicaltrials.gov/study/NCT04059913>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04059913

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 318 participants.

## Technical summary

Registry record NCT04059913. Randomized; no masking; primary purpose treatment. Start 2019-06-11 (actual); primary completion 2021-11-19 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 318 participants (enrolled count; ClinicalTrials.gov record NCT04059913, source copy `cardio:ctgov-nct04059913-2022-05-06`, retrieved 2026-10-26)
- Started: 2019-06-11 (actual) (ClinicalTrials.gov record NCT04059913, source copy `cardio:ctgov-nct04059913-2022-05-06`, retrieved 2026-10-26)
- Primary completion: 2021-11-19 (actual) (ClinicalTrials.gov record NCT04059913, source copy `cardio:ctgov-nct04059913-2022-05-06`, retrieved 2026-10-26)
- Completion: 2021-12-17 (actual) (ClinicalTrials.gov record NCT04059913, source copy `cardio:ctgov-nct04059913-2022-05-06`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04059913, source copy `cardio:ctgov-nct04059913-2022-05-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04059913-2022-05-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease
- Condition: CKD Anemia in Dialysis Participants
- Intervention (Drug): Roxadustat
- Lead sponsor: Kyntra Bio
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Kyntra Bio (`cardio:org-kyntra-bio`)

## Provenance

Content hash: bfc010cd4bb8d5e8c4e37993c353da03ddbb25f20161ebc19ae8bb3f2d524c35
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
